Abstract
Although molecular analysis of tumor material is standard of care in patients with metastatic non-squamous non-small cell lung cancer, this is not always feasible. In daily practice it can be difficult to obtain tumor tissue or there may be insufficient tissue available for molecular investigation. This leaves possible targeted-treatment options unidentified in a subset of patients.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
